ReviewJournal of clinical medicine2025
Beyond Iron: The Roles of CD71 in the Pathophysiology of Cancer-A Comprehensive Review.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical-stage human anti-transferrin receptor antibodies suppress colorectal cancer metastasis.Signal transduction and targeted therapy · 2026Article
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD71, also known as transferrin receptor 1 (TfR1), is a transmembrane glycoprotein essential for cellular iron uptake, a prerequisite for cell proliferation, differentiation, and survival. While its canonical role in iron metabolism is well documented, accumulating research highlights CD71's broader involvement in oncogenic processes that extend far beyond iron regulation. This review provides an overview of recent advances in understanding the multifaceted roles of CD71 within cancer biology. Specifically, we examine how CD71 participates in key cancer-related mechanisms, including modulation of intracellular signaling cascades, such as MAPK/ERK and PI3K/AKT pathways. We also mention the impact on regulation of apoptosis and autophagy, and orchestration of dynamic interactions within the tumor microenvironment such as adhesion/invasion and immune evasion. Emerging evidence indicates that CD71 not only sustains tumor growth and cancer cell proliferation through enhanced iron acquisition but also promotes metastasis, immune evasion, and therapy resistance. Moreover, CD71 contributes to the crosstalk between cancer and chronic diseases, with notable implications for cardiac, neurological, and gastrointestinal conditions often linked to malignancy. Through a comprehensive synthesis of current findings, we elucidate the complex and evolving roles of CD71 in cancer progression and therapy and provide an up-to-date account of its biology and pathophysiology. This review underscores the importance of understanding CD71 not only in oncology but also across the broader field of chronic diseases associated with malignancy. We suggest that future work should advance innovative therapeutic approaches that leverage CD71's dual roles in cancer biology and systemic disease management to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.